All In Biotech

Drug Trial Radar · NCT07593911

A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases

An Open-Label, Single-Arm, Dose-Escalation and Expansion Basket Study Evaluating the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Efficacy of MTM-H-001 in Patients With B-Cell-Related Autoimmune Diseases (ArchAid-002)

Last checked: Nov 19, 2026Latest source record: May 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Jun 2026

Primary completion

Nov 2030

Study completion Jun 2031

Sponsor

Lead sponsor
Beijing GoBroad HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
MagicTime Medicine
First posted
May 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an investigator-initiated, open-label, single-arm, dose-escalation and dose-expansion study to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of MTM-H-001 in adult participants with B-cell-related autoimmune diseases.

Conditions

  • Systemic Lupus Erthematosus (SLE)
  • Lupus Nephritis (LN)
  • Multiple Sclerosis
  • Myasthenia Gravis (MG)
  • IgG4-Related Diseases
  • Rheumatoid Arthritis (RA)

Interventions

  • MTM-H-001 InjectionDrug

    Each participant receives MTM-H-001 Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose-Limiting Toxicity (DLT)Time frame: 42 days following first dose of MTM-H-001 for each participant

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing GoBroad Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.